Jingmai Medical

Jingmai Medical focuses on intelligent navigation and robotic systems for precision surgery, with particular emphasis on thoracic and abdominal tumor interventions. The company achieved a significant milestone in August 2021 when both its Puncture Surgery Navigation System and Disposable Electromagnetic Positioning Needle received NMPA Class III medical device registration certificates.

Company Overview

Founded in 2016 in Shanghai, Jingmai Medical has positioned itself as a pioneer in the precision oncology intervention space. The company combines deep learning algorithms, sensor network technologies, and virtual reality visualization to create broad surgical navigation solutions.

The founding team brings over a decade of experience in precision surgical instrumentation, enabling rapid development of clinically validated products. By 2021, the company had completed over 200 clinical cases with its navigation system, achieving positioning accuracy within 3mm—a critical threshold for early-stage cancer detection and treatment.

Core Products

Puncture Surgery Navigation System

The flagship product integrates C-arm and CT imaging data with virtual reality 3D immersive scenes, providing surgeons with real-time intelligent guidance. Key capabilities include:

• Automated pre-operative registration using deep learning
• Respiratory drift correction during procedures
• Image display and tissue segmentation
• 3D modeling and surgical path planning
• Post-operative reporting

Disposable Electromagnetic Positioning Needle

China’s first intelligent navigation puncture needle, this consumable device works in conjunction with the navigation system to provide real-time positional feedback. The needle enables precise targeting of lesions while maintaining continuous tracking throughout the procedure.

Technology & Innovation

The navigation platform addresses a fundamental challenge in percutaneous interventions: respiratory motion compensation. Traditional CT-guided biopsies require patients to hold their breath, limiting accuracy for deep-seated lesions. Jingmai’s system incorporates real-time respiratory drift correction, maintaining targeting accuracy even during normal breathing patterns.

The integration of virtual reality visualization allows surgeons to plan and execute procedures in a 3D immersive environment, reducing the learning curve for complex interventional techniques.

Clinical Applications

The system supports multiple interventional oncology procedures:

• Diagnostic biopsy of thoracic and abdominal tumors
• Thermal ablation (radiofrequency, microwave, cryoablation)
• Positioning hook placement for surgical resection
• Radioactive seed implantation (brachytherapy)
• Intratumoral drug delivery
• Irreversible electroporation (NanoKnife)

Clinical validation across tier-three hospitals has demonstrated consistent accuracy below 3mm, meeting requirements for early lung cancer nodule biopsy (≤8mm) as specified in China’s 2021 lung cancer screening guidelines.

Market Presence

The company targets both tertiary hospitals for advanced oncology programs and primary healthcare facilities seeking to expand interventional capabilities. The simplified workflow and safety features of the navigation system aim to democratize precision interventional techniques beyond major academic centers.

Key Milestones

• 2016: Company founded in Shanghai
• 2021 (March): Completed Series A financing led by Cardite Medical (Chia Tai Pharmaceutical Group), totaling several hundred million RMB
• 2021 (August): Both Puncture Surgery Navigation System and Electromagnetic Positioning Needle received NMPA Class III certificates
• 2021: Accumulated over 200 clinical cases with sub-3mm accuracy

Frequently Asked Questions

What types of procedures does Jingmai’s navigation system support?

The system supports diagnostic biopsies, thermal ablations (radiofrequency, microwave, cryo), seed implantation for brachytherapy, and intratumoral drug delivery for thoracic and abdominal tumors.

How accurate is the Jingmai puncture navigation system?

Clinical studies have demonstrated positioning accuracy within 3mm, meeting the requirements for early lung cancer nodule biopsy as defined in China’s 2021 screening guidelines.

Is Jingmai Medical’s navigation system NMPA approved?

Yes, both the Puncture Surgery Navigation System and the Disposable Electromagnetic Positioning Needle received NMPA Class III medical device registration certificates in August 2021.